{"id":2456,"date":"2017-03-01T12:02:00","date_gmt":"2017-03-01T11:02:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2017\/trastuzumab-nach-adjuvanter-chemotherapie-des-her2-positiven-mammakarzinoms-langzeitergebnisse-der-hera-studie"},"modified":"2017-03-01T12:02:00","modified_gmt":"2017-03-01T11:02:00","slug":"trastuzumab-nach-adjuvanter-chemotherapie-des-her2-positiven-mammakarzinoms-langzeitergebnisse-der-hera-studie","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2017\/trastuzumab-nach-adjuvanter-chemotherapie-des-her2-positiven-mammakarzinoms-langzeitergebnisse-der-hera-studie","title":{"rendered":"Trastuzumab nach adjuvanter Chemotherapie des HER2-positiven Mammakarzinoms: Langzeitergebnisse der HERA-Studie"},"content":{"rendered":"<p>Wir hatten 2006 ausf\u00fchrlich \u00fcber die Ergebnisse der damals publizierten vier Phase-III-Studien an etwa 7.000 Patientinnen mit HER2-positivem Mammakarzinom (HER2 = Humaner &#8222;Epidermal growth factor Receptor 2&#8222;) berichtet (1). Diese Studien hatten ein unterschiedliches Design, und die Dauer der Nachbeobachtung war zum Zeitpunkt ihrer Publikation noch kurz. Zu diesen Studien geh\u00f6rt auch die HERA-(HERceptin Adjuvant [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Wir hatten 2006 ausf\u00fchrlich \u00fcber die Ergebnisse der damals publizierten vier Phase-III-Studien an etwa 7.000 Patientinnen mit HER2-positivem Mammakarzinom (HER2 = Humaner &#8222;Epidermal growth factor Receptor 2&#8222;) berichtet (1). Diese Studien hatten ein unterschiedliches Design, und die Dauer der Nachbeobachtung war zum Zeitpunkt ihrer Publikation noch kurz. Zu diesen Studien geh\u00f6rt auch die HERA-(HERceptin Adjuvant [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[146,1903,3886,1906,1508,222,149,1884],"class_list":["post-2456","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-brustkrebs","tag-her2","tag-hera-studie","tag-human-epidermal-growth-factor-receptor-2","tag-kardiotoxizitaet","tag-karzinome","tag-mammakarzinom","tag-trastuzumab"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2456","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=2456"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2456\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=2456"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=2456"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=2456"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}